Education
About Us
Working with TipRanks
Follow Us
Stuart Collinson Insider Profile
4 Followers
Stuart Collinson, Director at Vertex Pharmaceuticals, holds 3.28K shares in Vertex Pharmaceuticals (Ticker: VRTX), holds 1.02K shares in Soleno Therapeutics (Ticker: SLNO). Most recently, Stuart Collinson ― shares of Vertex Pharmaceuticals on ― for an estimated value of ―.
Stuart Collinson has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Stuart Collinson holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Stuart Collinson
Stuart Collinson's Trading History
Vertex Pharmaceuticals
―
Director
―
$1.60M
Soleno Therapeutics
Aug 03, 2020
Director
Uninformative Buy
1.75K
$45.59K
List of latest transactions for each holding click on a transaction to see Stuart Collinson's performance on stock
You May Also Like
Stuart Collinson insider profile FAQ
What is the percentage of profitable transactions made by Stuart Collinson?
The percentage of profitable transactions made by Stuart Collinson is ―.
What is the average return per transaction made by Stuart Collinson?
The average return per transaction made by Stuart Collinson is ―.
What stocks does Stuart Collinson hold?
Stuart Collinson holds: VRTX, SLNO stocks.
What was Stuart Collinson’s latest transaction?
Stuart Collinson latest transaction was an Uninformative Buy of ―.
What was Stuart Collinson's most profitable transaction?
Stuart Collinson’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Stuart Collinson's role in Vertex Pharmaceuticals?
Stuart Collinson's role in Vertex Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.